Skip to main content

Table 1 Summary characteristics of included studies and participants according to achieved systolic blood pressure groups

From: Achieved systolic blood pressure in older people: a systematic review and meta-analysis

Study name (year)

FU (months)

SBPTa

study

P-h/sa of RCTs analysis

N participants

Antihypertensive

Age (SD)

Women (%)

Hypertension

(%)

Diabetes

(%)

Smoking (%)

Previous coronary disease

(%)

Previous cerebrovascular disease (%)

Intervention

Control

Intervention

Control

140 to < 150 mmHg

 HOT [14] (2000)

45

No

Yes

nd

nd

Thiazide, BB, CCB or ACEi

Thiazide, BB, CCB or ACEi

70.6 (3.9)

54

100

10

11

13

130 to < 140 versus ≥ 140 mmHg

 EWPHE [30] (1989)

9

Yes

Yes

120

126

thiazide + triamterene

thiazide + triamterene

71.4 (6.9)

70

100

nd

19

35

 JATOS [10] (2008)

24

Yes

No

2212

2206

CCB

CCB

73.6 (5.2)

61

100

11

13

3

4

 VALISH [11] (2010)

33

Yes

No

1545

1534

ARB

ARB

76.1 (4.1)

62

100

13

19

5

6

 ADVANCE [28] (2010) 65–74 yo

51

No

Yes

2845

2760

Thiazide + ACEi

Placebo + usual antiHTN drug treatmentc

68 (nd)

42

61

100

10

11

8

 ADVANCE [28] (2010) ≥ 75 yo

51

No

Yes

490

518

Thiazide + ACEi

Placebo + usual antiHTN drug treatmentc

77 (nd)

40

67

100

6

16

12

 FEVER [21] (2011)

40

Yes

Yes

1631

1548

Thiazide + CCB

Thiazide + Placebo

> 65

61b

100

12b

29b

2b

10b

 Wei et al. [24] (2013)

48

Yes

No

363

361

Thiazide, ACEi, BB or CCB

Thiazide, ACEi, BB or CCB

76.5 (4.5)

33

100

23

24

nd

6

 INVEST [27] (2014)

24

Yes

Yes

4787

1747

CCB/ACEi or BB/thiazide

CCB/ACEi or BB/thiazide

70.7 (7.3)

55

100

29

42

100

8

< 130 versus ≥ 130 mmHg

 LIFE [22] (2012)

55

Yes

Yes

5704e

ARB or BB

ARB or BB

≥ 65

54b

100

13b

16b

16b

4b

 SPS3 [12] (2015)

42

Yes

Yes

248

246

Any

Any

79.9 (3.8)

45

77

27

5

10

100

 SPRINT [13, 31] (2016)

37

Yes

Nod

1317

1319

Any

Any

79.8 (4)

38

nd

0

13b

24,5

0

  1. FU Follow-up time, SBPT Systolic blood pressure target, P-h/sa of RCTs Post-hoc analyses and subanalyses of randomized controlled trials, SD Standard deviation, BB, Beta-blocker, CCB Calcium channel blocker, ACEi Angiotensin converter enzyme inhibitor, ARB, angiotensin receptor blocker, antiHTN drug treatment Antihypertensive drug treatment, nd Not described. aSystolic blood pressure target study refers to analysis of different systolic blood pressure targets on cardiovascular outcomes or all-cause mortality. Therefore, studies that are not blood pressure target driven were included based on the criteria of having at least 3 mmHg systolic blood pressure difference between intervention and control group. b data retrieved from whole population. c hypertensive participants received antihypertensive treatment; d SPRINT trial evaluated the elderly population as a prespecified analysis. e data was combined from intervention and control groups